

Author reply

Sir,

The European Heart Rhythm Association guidelines on the new orally available anticoagulants in patients of atrial fibrillation as mentioned in the letter definitely provide a more rational and a practical approach to the use of these agents. Guidelines have highlighted the concern for various existing and possible drug interactions for apixaban, rivaroxaban and dabigatran. The outcome of interactions of various drugs with apixaban is still awaited but nevertheless, the guidelines have emphasized caution for usage of such drugs with apixaban.

As far as the use of these drugs in the patients with deranged renal functions is concerned, it was considered unsafe, but the guidelines have provided us with the definite value of creatinine clearance beyond which none of these drugs can be used.

The information provided in the letter is useful and will enable the readers toward judicious use of new oral anticoagulants.

Sangeeta Bhanwra, Kaza Ahluwalia

Department of Pharmacology, Government Medical College and Hospital, Sector-32 B, Chandigarh, India

Address for correspondence:

Sangeeta Bhanwra, House No. 1152, Sector-32 B, Chandigarh - 160 030, India. E-mail: doc_sangeeta@yahoo.com

Received: 08-02-2014

Revised: 24-02-2014

Accepted: 24-02-2014

Access this article online

Quick Response Code:



Website:
www.jpharmacol.com